Payment overview · 2025
General Payments
$675.28
47 reported records · 14 companies
Healthcare provider profile · identity verified
Amer R Malik, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LYNN HAVEN, FL · NPI 1932207461
Verified facts
What the public records show
CMS Open Payments records show Amer R Malik, M.D. received $675.28 in general payments during 2025 across 47 reported records.
Novo Nordisk Inc accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $176.09 | 26.1% | 25 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $104.70 | 15.5% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $60.54 | 9.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.47 | 8.5% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $54.21 | 8.0% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $42.71 | 6.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.95 | 5.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $32.03 | 4.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $30.51 | 4.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.77 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.71 | 2.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.94 | 2.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.55 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.10 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $675.28 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $150.40 | 22 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $82.79 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $60.54 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $54.21 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.16 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $46.45 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $42.71 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.96 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $32.03 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 173 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
41 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
240 | 68 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
72 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
173 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1136 | 342 |
| Montelukast Sodium | Montelukast Sodium | 983 | 248 |
| Levothyroxine Sodium | Levothyroxine Sodium | 811 | 206 |
| Omeprazole | Omeprazole | 729 | 202 |
| Alprazolam | Alprazolam | 708 | 105 |
| Losartan Potassium | Losartan Potassium | 637 | 174 |
| Amlodipine Besylate | Amlodipine Besylate | 603 | 168 |
| Carvedilol | Carvedilol | 515 | 148 |
| Potassium Chloride | Potassium Chloride | 469 | 124 |
| Gabapentin | Gabapentin | 399 | 108 |
| Hydrochlorothiazide | Hydrochlorothiazide | 379 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 375 | 104 |
| Prednisone | Prednisone | 365 | 217 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 341 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 315 | 93 |
| Lisinopril | Lisinopril | 302 | 89 |
| Simvastatin | Simvastatin | 295 | 79 |
| Metformin Hcl | Metformin Hcl | 285 | 81 |
| Furosemide | Furosemide | 256 | 78 |
| Alendronate Sodium | Alendronate Sodium | 253 | 75 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 245 | 35 |
| Jardiance | Empagliflozin | 240 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 235 | 60 |
| Tramadol Hcl | Tramadol Hcl | 234 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 67 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 214 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 210 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 53 |
| Cefdinir | Cefdinir | 175 | 139 |
| Ozempic | Semaglutide | 173 | 34 |
| Trazodone Hcl | Trazodone Hcl | 172 | 55 |
| Meloxicam | Meloxicam | 168 | 51 |
| Allopurinol | Allopurinol | 160 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 158 | 52 |
| Doxycycline Hyclate | Doxycycline Hyclate | 148 | 107 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 137 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 45 |
| Januvia | Sitagliptin Phosphate | 134 | 37 |
| Methocarbamol | Methocarbamol | 128 | 45 |
| Glimepiride | Glimepiride | 120 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 19 |
| Aripiprazole | Aripiprazole | 113 | 32 |
| Clonazepam | Clonazepam | 112 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 112 | 25 |
| Sertraline Hcl | Sertraline Hcl | 111 | 35 |
| Azithromycin | Azithromycin | 110 | 87 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 110 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 32 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 103 | 32 |
| Eliquis | Apixaban | 102 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 32 |
| Ezetimibe | Ezetimibe | 100 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 22 |
| Celecoxib | Celecoxib | 98 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 28 |
| Famotidine | Famotidine | 95 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 24 |
| Dexamethasone | Dexamethasone | 88 | 78 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 85 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 84 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 24 |
| Lorazepam | Lorazepam | 78 | 27 |
| Diazepam | Diazepam | 77 | 13 |
| Spironolactone | Spironolactone | 74 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 21 |
| Trulicity | Dulaglutide | 72 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 14 |
| Baclofen | Baclofen | 69 | 17 |
| Topiramate | Topiramate | 69 | 17 |
| Bupropion Xl | Bupropion Hcl | 68 | 16 |
| Glipizide | Glipizide | 68 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 18 |
| Sucralfate | Sucralfate | 66 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 14 |
| Buspirone Hcl | Buspirone Hcl | 63 | 14 |
| Mounjaro | Tirzepatide | 63 | suppressed |
| Pregabalin | Pregabalin | 62 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 61 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 13 |
| Nitroglycerin | Nitroglycerin | 58 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 18 |
| Benazepril Hcl | Benazepril Hcl | 55 | 15 |
| Xarelto | Rivaroxaban | 55 | 13 |
| Valacyclovir | Valacyclovir Hcl | 54 | 15 |
| Clonidine Hcl | Clonidine Hcl | 51 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 49 | 11 |
| Digoxin | Digoxin | 48 | 12 |
| Levetiracetam | Levetiracetam | 48 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 48 | 16 |
| Chlorthalidone | Chlorthalidone | 47 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 14 |
| Gemfibrozil | Gemfibrozil | 43 | suppressed |
| Entresto | Sacubitril/Valsartan | 42 | 11 |
| Ibuprofen | Ibuprofen | 42 | 12 |
| Linzess | Linaclotide | 42 | 11 |
| Primidone | Primidone | 42 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 41 | 41 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | 13 |
| Estradiol | Estradiol | 40 | 12 |
| Metformin Hcl Er | Metformin Hcl | 40 | 13 |
| Atenolol | Atenolol | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 21 |
| Fluconazole | Fluconazole | 37 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 17 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 34 | 13 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 34 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 26 |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 32 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 27 |
| Amoxicillin | Amoxicillin | 31 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 29 |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 11 |
| Klor-Con 10 | Potassium Chloride | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 25 |
| Dutasteride | Dutasteride | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 16 |
| Anastrozole | Anastrozole | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 11 |
| Nystatin | Nystatin | 13 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $675.28 · 47 records | Novo Nordisk Inc | ACCRUFER, AIRSUPRA, Azstarys, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, INSPIRE, KISUNLA, LEQVIO, Ozempic, QULIPTA, REXULTI, UBRELVY, VRAYLAR, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error